Clinical, GH response to GHRH and Arg compared to Arg, and insulin and MRI findings in the prepuberal children with congenital hypopituitarism at the time of diagnosis
| Case no./Sex . | Age (yr) . | Ht (sd score) . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arginine . | Insulin/glucagon . | GHRH plus Arg . | ||||||
| 1/M | 2.7 | −2.7 | 35 | 1.7 | 0.7 | 34.3 | GH | VPS |
| 2/M | 3.9 | −2.8 | 42 | 3.3 | 1.1 | 31.7 | GH | VPS |
| 3/F | 2.7 | −1.9 | 27 | 4.3 | 6.6 | 40.2 | GH | VPS |
| 4/F | 3.6 | −2.4 | 33 | 4.7 | 3.5 | 17.3 | GH | VPS |
| 5/M | 3.5 | −2.7 | 36 | 3.5 | 2.8 | 36.8 | GH | VPS |
| 6/M | 4.7 | −2.0 | 39 | 5.6 | 2.8 | 18.8 | GH | VPS |
| 7/M | 5.2 | −2.1 | 38 | 3.8 | 4.7 | 21.6 | GH | VPS |
| 8/M | 3.0 | −2.6 | 29 | 3.8 | 4.7 | 6.1 | GH | PSA |
| 9/F | 3.4 | −3.2 | 41 | 4.5 | 4.8 | 4.5 | GH | PSA |
| 10/M | 2.8 | −2.5 | 28 | 3.8 | 3.2 | 6.9 | GH | PSA |
| 11/F | 4.6 | −4.2 | 49 | 2.5 | 3 | 8.8 | GH | PSA |
| 12/M | 4.6 | −3.0 | 36 | 4.1 | 3.6 | 4.4 | GH+TSH | PSA |
| 13/F | 1.0 | −2.0 | 38 | 3.2 | 4.8 | 3.1 | GH+TSH | PSA |
| 14/M | 4.0 | −2.2 | 22 | 4.4 | 3.1 | 3.2 | GH+TSH | PSA |
| 15/M | 4.9 | −2.3 | 44 | 3.7 | 4.1 | 3.2 | GH+TSH | PSA |
| 16/M | 3.9 | −2.0 | 45 | 5.1 | 4.9 | 7.6 | GH+TSH+ACTH | PSA |
| 17/M | 3.9 | −3.9 | 31 | 2.7 | 5.6 | 2.4 | GH+TSH+ACTH | PSA |
| Case no./Sex . | Age (yr) . | Ht (sd score) . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arginine . | Insulin/glucagon . | GHRH plus Arg . | ||||||
| 1/M | 2.7 | −2.7 | 35 | 1.7 | 0.7 | 34.3 | GH | VPS |
| 2/M | 3.9 | −2.8 | 42 | 3.3 | 1.1 | 31.7 | GH | VPS |
| 3/F | 2.7 | −1.9 | 27 | 4.3 | 6.6 | 40.2 | GH | VPS |
| 4/F | 3.6 | −2.4 | 33 | 4.7 | 3.5 | 17.3 | GH | VPS |
| 5/M | 3.5 | −2.7 | 36 | 3.5 | 2.8 | 36.8 | GH | VPS |
| 6/M | 4.7 | −2.0 | 39 | 5.6 | 2.8 | 18.8 | GH | VPS |
| 7/M | 5.2 | −2.1 | 38 | 3.8 | 4.7 | 21.6 | GH | VPS |
| 8/M | 3.0 | −2.6 | 29 | 3.8 | 4.7 | 6.1 | GH | PSA |
| 9/F | 3.4 | −3.2 | 41 | 4.5 | 4.8 | 4.5 | GH | PSA |
| 10/M | 2.8 | −2.5 | 28 | 3.8 | 3.2 | 6.9 | GH | PSA |
| 11/F | 4.6 | −4.2 | 49 | 2.5 | 3 | 8.8 | GH | PSA |
| 12/M | 4.6 | −3.0 | 36 | 4.1 | 3.6 | 4.4 | GH+TSH | PSA |
| 13/F | 1.0 | −2.0 | 38 | 3.2 | 4.8 | 3.1 | GH+TSH | PSA |
| 14/M | 4.0 | −2.2 | 22 | 4.4 | 3.1 | 3.2 | GH+TSH | PSA |
| 15/M | 4.9 | −2.3 | 44 | 3.7 | 4.1 | 3.2 | GH+TSH | PSA |
| 16/M | 3.9 | −2.0 | 45 | 5.1 | 4.9 | 7.6 | GH+TSH+ACTH | PSA |
| 17/M | 3.9 | −3.9 | 31 | 2.7 | 5.6 | 2.4 | GH+TSH+ACTH | PSA |
VPS, Vascular pituitary stalk; PSA, pituitary stalk agenesis.
Clinical, GH response to GHRH and Arg compared to Arg, and insulin and MRI findings in the prepuberal children with congenital hypopituitarism at the time of diagnosis
| Case no./Sex . | Age (yr) . | Ht (sd score) . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arginine . | Insulin/glucagon . | GHRH plus Arg . | ||||||
| 1/M | 2.7 | −2.7 | 35 | 1.7 | 0.7 | 34.3 | GH | VPS |
| 2/M | 3.9 | −2.8 | 42 | 3.3 | 1.1 | 31.7 | GH | VPS |
| 3/F | 2.7 | −1.9 | 27 | 4.3 | 6.6 | 40.2 | GH | VPS |
| 4/F | 3.6 | −2.4 | 33 | 4.7 | 3.5 | 17.3 | GH | VPS |
| 5/M | 3.5 | −2.7 | 36 | 3.5 | 2.8 | 36.8 | GH | VPS |
| 6/M | 4.7 | −2.0 | 39 | 5.6 | 2.8 | 18.8 | GH | VPS |
| 7/M | 5.2 | −2.1 | 38 | 3.8 | 4.7 | 21.6 | GH | VPS |
| 8/M | 3.0 | −2.6 | 29 | 3.8 | 4.7 | 6.1 | GH | PSA |
| 9/F | 3.4 | −3.2 | 41 | 4.5 | 4.8 | 4.5 | GH | PSA |
| 10/M | 2.8 | −2.5 | 28 | 3.8 | 3.2 | 6.9 | GH | PSA |
| 11/F | 4.6 | −4.2 | 49 | 2.5 | 3 | 8.8 | GH | PSA |
| 12/M | 4.6 | −3.0 | 36 | 4.1 | 3.6 | 4.4 | GH+TSH | PSA |
| 13/F | 1.0 | −2.0 | 38 | 3.2 | 4.8 | 3.1 | GH+TSH | PSA |
| 14/M | 4.0 | −2.2 | 22 | 4.4 | 3.1 | 3.2 | GH+TSH | PSA |
| 15/M | 4.9 | −2.3 | 44 | 3.7 | 4.1 | 3.2 | GH+TSH | PSA |
| 16/M | 3.9 | −2.0 | 45 | 5.1 | 4.9 | 7.6 | GH+TSH+ACTH | PSA |
| 17/M | 3.9 | −3.9 | 31 | 2.7 | 5.6 | 2.4 | GH+TSH+ACTH | PSA |
| Case no./Sex . | Age (yr) . | Ht (sd score) . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arginine . | Insulin/glucagon . | GHRH plus Arg . | ||||||
| 1/M | 2.7 | −2.7 | 35 | 1.7 | 0.7 | 34.3 | GH | VPS |
| 2/M | 3.9 | −2.8 | 42 | 3.3 | 1.1 | 31.7 | GH | VPS |
| 3/F | 2.7 | −1.9 | 27 | 4.3 | 6.6 | 40.2 | GH | VPS |
| 4/F | 3.6 | −2.4 | 33 | 4.7 | 3.5 | 17.3 | GH | VPS |
| 5/M | 3.5 | −2.7 | 36 | 3.5 | 2.8 | 36.8 | GH | VPS |
| 6/M | 4.7 | −2.0 | 39 | 5.6 | 2.8 | 18.8 | GH | VPS |
| 7/M | 5.2 | −2.1 | 38 | 3.8 | 4.7 | 21.6 | GH | VPS |
| 8/M | 3.0 | −2.6 | 29 | 3.8 | 4.7 | 6.1 | GH | PSA |
| 9/F | 3.4 | −3.2 | 41 | 4.5 | 4.8 | 4.5 | GH | PSA |
| 10/M | 2.8 | −2.5 | 28 | 3.8 | 3.2 | 6.9 | GH | PSA |
| 11/F | 4.6 | −4.2 | 49 | 2.5 | 3 | 8.8 | GH | PSA |
| 12/M | 4.6 | −3.0 | 36 | 4.1 | 3.6 | 4.4 | GH+TSH | PSA |
| 13/F | 1.0 | −2.0 | 38 | 3.2 | 4.8 | 3.1 | GH+TSH | PSA |
| 14/M | 4.0 | −2.2 | 22 | 4.4 | 3.1 | 3.2 | GH+TSH | PSA |
| 15/M | 4.9 | −2.3 | 44 | 3.7 | 4.1 | 3.2 | GH+TSH | PSA |
| 16/M | 3.9 | −2.0 | 45 | 5.1 | 4.9 | 7.6 | GH+TSH+ACTH | PSA |
| 17/M | 3.9 | −3.9 | 31 | 2.7 | 5.6 | 2.4 | GH+TSH+ACTH | PSA |
VPS, Vascular pituitary stalk; PSA, pituitary stalk agenesis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
